Genetic PCSK9 inhibition via base editing appeared safe and demonstrated dose-dependent, durable reductions in PCSK9 and LDL cholesterol, researchers reported.At the highest dose, VERVE-102 (Verve ...

An experimental gene-editing therapy that aims to lower bad cholesterol for the long-term after a single infusion is off to a ...

Eli Lilly is laying the groundwork for a phase 2 trial of the lipid-lowering gene editor it acquired from Verve Therapeutics, with the candidate now showing strong and consistent cholesterol ...

A groundbreaking gene-editing therapy developed by Eli Lilly and Verve Therapeutics reduced "bad" LDL cholesterol by up to 62 ...

Tweaked lipid nanoparticle delivery system showed early safety ...

In a step toward treating mitochondrial diseases, researchers at the University Medical Center Utrecht and their colleagues have used mitochondrial base editing (mtBE) to successfully edit harmful ...

You may have seen it in the news recently: a baby in Pennsylvania with a rare genetic disorder was healed with a personalized treatment that repaired his specific genetic mutation. The treatment was ...

The trajectory of base editing has been remarkable, progressing from the laboratory to patient care, treating debilitating or terminal illnesses, in less than a decade. A type of gene editing that ...

In this talk in GEN’s “The State of CRISPR & Genome Editing” virtual summit, originally broadcast on June 11, 2025, Alexis Komor, PhD, Associate Professor at University of California San Diego and ...

The success of the approach is particularly significant, Lutz said, because it applies base editing to one of the most difficult settings for genetic medicine: a neurological disorder involving ...

Prion diseases are a group of rare infectious neurodegenerative diseases caused by modifications in the prion protein (PrP) that prompt it to misfold. 1 Invariably fatal, prion disease can be genetic, ...

Forbes contributors publish independent expert analyses and insights. Juergen Eckhardt leads Bayer’s impact investment unit, Leaps by Bayer. Dr. David Liu, pictured with former lab members Holly Rees ...